



PRESS RELEASE

Crucell to Webcast Analyst Day on November 16, 2004

Leiden, The Netherlands, November 5, 2004 – Crucell N.V. (Euronext, NASDAQ: CRXL), invites investors, the media and the general public to view a live video webcast of its Analyst Day Meeting at 2.30pm CET (8.30am US Eastern time) on Tuesday, November 16, 2004.

During the meeting, Crucell will present a comprehensive update on the company's product development plans and progress, including the most recent data available on its product programs.

The live video webcast can be accessed via the homepage of Crucell's website at <http://www.crucell.com>, and will be archived and available for replay following the event. The meeting is expected to last approximately three hours.

About Crucell

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria and West Nile virus. The company's development programs include collaborations with Aventis Pasteur for influenza vaccines, the U.S. National Institutes of Health for Ebola and malaria vaccines, and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its innovative PER.C6[®] technology, which offers a safer, more efficient way to produce biopharmaceuticals. The company licenses its PER.C6[®] technology to the biopharmaceutical industry on a mostly non-exclusive basis. Licensees and CMO partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit www.crucell.com.

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 18, 2003, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).



For further information please contact:

Crucell N.V.

Elizabeth Goodwin
Director Investor Relations and
Corporate Communications
Tel. +31 (0)71 524 8718
e.goodwin@crucell.com

**For Crucell N.V. in the USA:
Redington Inc.**

Thomas Redington
Tel. +1 212-926-1733
tredington@redingtoninc.com